Cramer's Morning Take: Eli Lilly 8/7/25

Squawk on the Street

CNBC

News, Business, Investing

4.1 • 567 Ratings

🗓️ 7 August 2025

⏱️ 4 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Cramer reacts to this pharma giant’s drug trial that failed to impress. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Transcript

Click on a timestamp to play from that location

0:00.0	Hey, it's Kramer, and this is my morning take on the market from today's
0:05.3	CNBC Investing Club morning meeting.
0:07.5	We sold 25 shares of Lilly last week.
0:11.7	775 was about a fifth of the position that was after NOVA reported, said some disturbing
0:18.3	things about the GLP1 market.
0:21.8	The trade was a hedge against Lilly saying disappointing things too.
0:25.5	Ironically, Lilly's quarter was actually good.
0:27.9	It was a beat and raise, Minjaro beat, set-bound beat.
0:30.9	They're taking share in the obesity and type 2 diabetes market.
0:35.4	However, and this was a big shock. The pill data for the oral GLP1, disappointed.
0:41.3	It was a longer readout.
0:43.3	Weight loss, not as much as we expected.
0:47.3	Call it 12% for some, you know, 13 to 15.
0:51.3	Discontinuation rate's a little bit higher, although, you know, generally in line with
0:56.5	other GLP-1s.
0:58.0	This was not what we wanted.
1:00.3	No, no.
1:01.3	It's a disappointment.
1:02.8	And then the comp school not that great.
1:05.4	And David, whom I do like very much, David Ricks, know very well, is sticking by a thesis, which says, I don't
1:11.7	know what the problem is, why are you not like this, and our earnings were good. And Dave was
1:18.1	a little tone deaf, and that hurt the stock. Because I think that the stock did go up from
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from CNBC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of CNBC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.